amorchem header logo close button Menu
arrow leftBack to portfolio


Neurasic Therapeutics ( is a company based on the work of Philippe Seguela at McGill University’s Montreal Neurological Institute. In collaboration with adMare BioInnovations, the portfolio company is developing small molecule antagonists of the acid-sensing channel, ASIC1—an exciting alternative to targeting opioid receptors in the treatment of chronic pain which provides a novel approach to opiate-sparing.